Spots Global Cancer Trial Database for Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer
Official Title: Research on the Transformation of Postoperative Adjuvant Therapy of Tumor Antigen-sensitized DC Vaccine Applied to Esophagus Cancer
Study ID: NCT05023928
Interventions
Study Description
Brief Summary: The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
West China Hospital, Chengdu, Sichuan, China
Contact Details
Name: Zhen-Yu Ding, Prof
Affiliation: Sichuan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
